BioNTech Collaborations GmbH /
Biotheus
BioNTech Collaborations GmbH completes acquisition of Biotheus
Source for the buyer and target: BioNTech SE
For the buyer and target.
“On November 13, 2024, our subsidiary, BioNTech Collaborations GmbH, entered into an agreement and plan of merger, or the Merger Agreement, with Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases, to acquire 100 percent of the issued share capital of Biotheus.”
Published 12 Nov 2025
Open the sourceWhat happened
BioNTech Collaborations GmbH acquired Biotheus, a clinical-stage biotechnology company focused on developing novel antibodies for oncological and inflammatory diseases. The acquisition closed on January 31, 2025. [01]
The acquisition adds Biotheus’ pipeline candidates, research and development hub, biologics manufacturing facility and employees to BioNTech. [01]
The source
Everything on this page comes from the source below, quoted word for word.
BioNTech Collaborations GmbH completes acquisition of Biotheus
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly